Akari Therapeutics ( NASDAQ: AKTX ) in follow up to the May 1 st announcement that Samir R. Patel, has assumed the role of Interim President & CEO , provides detail of Dr. Patel’s employment compensation.
Dr. Patel’s employment contract reaffirms his desire to align his success directly with the success of the company's shareholders. Dr.
Patel will be compensated solely with equity, aligning his interests with Akari's shareholders. Dr. Patel's employment contract includes no cash compensation, severance package or performance bonuses.
More on Akari Therapeutics Akari gains despite leadership change amid portfolio shakeup Financial information for Akari Therapeutics.
